S. Koussa

Publications25
h-index8
Citations343
Highly Influential Citations12
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • A. Hoffbrand
  • 605 Publications, 18,083 Citations
  • B. Wonke
  • 130 Publications, 7,170 Citations
  • N. Olivieri
  • 242 Publications, 11,287 Citations
  • G. Brittenham
  • 181 Publications, 10,860 Citations
  • Publications
  • Influence
Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia
Thalassemia intermedia is a highly diverse group of thalassemia syndromes associated with anemia and a range of specific complications, such as extramedullary hematopoiesis, leg ulcers, gallstones… Expand
  • 95
  • 7
Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial
Osteoporosis is an important cause of morbidity in beta-thalassemia patients. Bisphosphonates have been recently used for the treatment of osteoporosis in beta-thalassemia. This study is a… Expand
  • 31
  • 2
Comparison between deferoxamine and deferiprone (L1) in iron‐loaded thalassemia patients
Abstract: Introduction: Iron‐chelating therapy with deferoxamine in patients with thalassemia major has dramatically improved the prognosis of this disease. However, the limitations of this treatment… Expand
  • 52
  • 1
Paradoxical Cerebral Embolism with a Patent Foramen ovale
Patent foramen ovale (PFO) is present in 25-30% of the population. Spontaneously, or with activities implying a Valsalva maneuver, a transient right-to-left shunt occurs. This can now be easily diagno
  • 51
  • 1
Syndrome de Eagle : apport du scanner avec reconstructions 3D
  • 23
  • 1
Efficacy and Side Effects of Deferiprone (L1) in Thalassemia Patients Not Compliant with Desferrioxamine
We report our experience with deferiprone (L1) (DFP) in 17 thalassemic patients, followed up in one center in Lebanon, who were initially on desferrioxamine and then shifted to DFP at a dose of 50–75… Expand
  • 21
Five-Year Trial of Deferiprone Chelation Therapy in Thalassaemia major Patients
Twelve thalassaemia major patients have been given deferiprone 75 mg/kg body weight daily as iron chelation therapy for 5 years. Their ages ranged from 18 to 34 years (mean 24.2) at the end of the… Expand
  • 21
Febrile Neutropenia and Hemorrhagic Stroke in a Thalassemia Major Patient
A 36-year-old transfusion-dependent thalassemia major patient presented with febrile neutropenia and anemia. Deferiprone (L1) was discontinued as it was suspected to be the offending agent and prompt… Expand
  • 3
Transfusion independence in Diamond-Blackfan anemia after deferasirox therapy
Abkowitz JL, 2002, BLOOD, V100, P2687, DOI 10.1182-blood.V100.8.2687; Di Tucci AA, 2007, EUR J HAEMATOL, V78, P540, DOI 10.1111-j.1600-0609.2007.00840.x; Janov AJ, 1996, MEDICINE, V75, P77, DOI… Expand
  • 7
The prediction of the particle laden gas flows
The problem of calculating particle laden flow, such as that in a PF combustor, is considered herein. The computational efficiencies of handling the particle phase on eulerian and lagrangian bases… Expand
  • 30